MARKETS
Earnings

Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate

Aug 12, 2026 · 07:34 AM ET· updated 2h ago

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from

Share
Why It Matters

Arbutus lost more money per share than experts thought it would, which is bad news. But their sales grew a lot, so the company is earning money from customers even though they're still spending more than they make.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.